Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) is a global medical technology company whose news flow centers on hospital technologies, plasma collection systems and blood center products. Company communications describe a focus on improving the quality, effectiveness and efficiency of health care, so news items often highlight developments that affect these areas.
Investors following HAE news can expect regular announcements about quarterly financial results, including the availability of earnings releases and details for conference calls and webcasts with investors and analysts. These updates are typically accompanied by Form 8-K filings that furnish the related press releases and summarize results for specific fiscal quarters.
Haemonetics also issues news about its participation in healthcare investment conferences, such as presentations at the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events provide additional context for the company’s strategy and operations in the medical technology space.
A notable category of news involves corporate transactions and interventional technologies. For example, Haemonetics announced the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation percutaneous vessel closure technology. Press releases describe how Vivasure’s PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore arterial and venous closure, is intended to expand Haemonetics’ range of closure devices and its presence in the large-bore closure market.
By monitoring the Haemonetics news page, readers can track earnings communications, conference participation, regulatory and acquisition-related updates, and other material events disclosed through press releases and SEC filings. This provides a consolidated view of developments affecting HAE within the surgical and medical instrument manufacturing industry.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Haemonetics Corporation (NYSE: HAE) has announced the schedule for its fourth quarter and fiscal year 2023 financial results. The results will be published on May 11, 2023, at 6:00 am ET, followed by a conference call with investors and analysts at 8:00 am ET the same day. Investors can access the call via a teleconference link provided in the announcement. Additionally, a live webcast will be available on the Haemonetics investor relations website. A replay of the call will be accessible for one year after the event. Haemonetics focuses on innovative medical products aimed at improving patient care and reducing healthcare costs, particularly in blood and plasma component collection and transfusion services.
Haemonetics Corporation (NYSE: HAE) announced the release of its first Corporate Responsibility Report on April 20, 2023. The report outlines the company's progress in environmental, social, and governance (ESG) initiatives for the fiscal year 2022, concluding on April 2, 2022. Key highlights include:
- Human capital initiatives aimed at attracting a diverse workforce.
- Results from the company's first greenhouse gas emissions assessment.
- Information on corporate governance, ethics, product safety, and cybersecurity.
CEO Christopher A. Simon emphasized the importance of addressing ESG risks and maintaining stakeholder trust. The report is available on Haemonetics' website.
Vivasure Medical announced its pivotal PATCH Clinical Study for the PerQseal® Closure Device has received FDA Investigational Device Exemption (IDE) approval. The study will enroll up to 188 patients in the U.S. and Europe, aiming for FDA pre-market approval and commercial launch by year-end 2023. The company also secured a €30 million strategic investment from Haemonetics as part of its Series D financing, with an option for acquisition upon milestone completion. The global market for large hole vessel closure is valued at over $300 million, with strong growth potential, emphasizing the significance of this partnership and study.
Haemonetics Corporation (NYSE: HAE) has received 510(k) clearance from the U.S. Food and Drug Administration for its next-generation Intelligent Control software for the Cell Saver Elite+ Autotransfusion System. This upgrade includes over 50 automation enhancements aimed at improving efficiency and user experience. The Cell Saver technology allows hospitals to recover patients' blood during surgeries, helping prevent unnecessary transfusions. The software upgrade enhances versatility, offering features such as Manual Mode and optimized wash volumes according to industry standards.
Haemonetics Corporation (NYSE: HAE) has announced that President and CEO Chris Simon will engage with investors during a fireside chat at the Raymond James 44th Annual Institutional Investors Conference on March 6, 2023, at 8:40 a.m. ET. The chat will be accessible via a live webcast on Haemonetics' Investor Relations website. After the event, a replay will be available for 90 days. Haemonetics specializes in innovative medical products aimed at improving patient care and lowering healthcare costs across critical medical markets, including blood and plasma collection.
Haemonetics Corporation (NYSE: HAE) announced that its third quarter fiscal 2023 financial results are accessible on its Investor Relations website. The reporting period ended on December 31, 2022. Investors and analysts are invited to a conference call on February 7, 2023, at 8:00 a.m. ET, to discuss these results. A live webcast will also be available. Earnings release and analytical tables have been posted online for review. For further information, visit Haemonetics' website.